Accessibility Menu
Mira Pharmaceuticals logo

Mira Pharmaceuticals(NASDAQ) MIRA

Market Cap$25.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-92%
5 YearN/A
1 Year-60%
1 Month-35%
$0.63
-20.69%
-0.16Today
Mira Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.612026-08-03
Mira Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-30.4%USD 0.882026-07-27
1 month-35.02%USD 0.942026-07-02
3 month-39.81%USD 1.022026-05-05
Year to date-59.34%USD 1.512025-12-31
1 year-60.14%USD 1.542025-08-01
3 year-89.79%USD 6.012023-08-04
Since inception-91.73%USD 7.422023-08-03

Mira Pharmaceuticals Financials at a Glance

Market Cap

$25.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.81M

EPS (TTM)

-$1.44

P/E Ratio

-0.43

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.63

Volume

14,896

Open

$0.78

Previous Close

$0.61

Daily Range

$0.60 - $0.85

52-Week Range

$0.60 - $2.45

Estimated Earnings Date

Sep 2, 2026

MIRA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mira Pharmaceuticals

MIRA develops oral medicines for pain, anxiety, and addiction. Its drugs aim to help adults with nerve pain or early dementia. The company focuses on new treatments for conditions with few current options.

Pills, Not Potions: What MIRA Sells

  • Ketamir-2: Oral drug for nerve pain, especially after chemotherapy; targets adults with chronic pain. (0% of revenue)
  • MIRA-55: Non-psychoactive cannabinoid pill for inflammatory pain and anxiety; in early testing. (0% of revenue)
  • SKNY-1: Oral treatment for obesity and nicotine addiction; targets adults seeking weight loss or to quit smoking. (0% of revenue)
  • MIRA1a: Synthetic cannabinoid for anxiety and pain; not in active development. (0% of revenue)

Growth Spurts and Strategic Moves

  • Acquired SKNY Pharmaceuticals in September 2025, adding SKNY-1 to its pipeline.
  • Completed Phase 1 trial for Ketamir-2 in March 2026; plans for Phase 2 trial in 2026.
  • Launched at-the-market (ATM) equity program in 2024 to raise capital for research.
  • Expanded patent filings and licenses in the US, Canada, and Mexico since 2024.

Why MIRA Is a Bit Different

MIRA focuses on oral drugs for pain, addiction, and metabolic disorders. Its medicines are not classified as controlled substances, which may ease development. The company relies on consultants and contract labs, keeping its employee count low.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; pre-commercial stage.
  • Net loss was $10.4 million in 2025, up approximately 33% from 2024.
  • Cash was $6.3 million at December 31, 2025; short-term investments $4.7 million.
  • Raised $6.7 million through ATM equity program in 2025.
  • Only two part-time employees; relies on outside consultants and service providers.

Bottom Line

MIRA remains a pre-revenue drug developer focused on oral therapies for pain and addiction. Its future depends on clinical progress and securing more funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Erez Aminov

Website

mirapharmaceuticals.com

Headquarters

Miami, FL 33131, US

MIRA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-140.83%

Return on Capital

-100.98%

Return on Assets

-103.65%

Earnings Yield

-2.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

42.02M

Volume

14.90K

Avg. Volume

102.32K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.79M

EBITDA

-$9.81M

Operating Cash Flow

-$4.23M

Capital Expenditure

$7.00

Free Cash Flow

-$4.23M

Cash & ST Invst.

$9.41M

Total Debt

$0.00

Mira Pharmaceuticals Performance Analysis

Mira Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Mira Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Mira Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.48223.5%
20232023-12-31USD -0.6535.2%
20242024-12-31USD -0.51-21.2%
20252025-12-31USD -1.35165.6%
Mira Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3017.7%
Q32025-09-30-1203.9%
Q42025-12-3188.1%
Q12026-03-3178.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$25.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.90M

N/A

Employees

2

N/A

Net Income

-$1.15M

+35.5%

EBITDA

-$1.15M

+35.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.41M

+679.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.04%

N/A

Return on Invested Capital

-1.05%

N/A

Free Cash Flow

-$1.20M

+26.3%

Operating Cash Flow

-$1.20M

+26.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TLPHTalphera, Inc.
$1.33+3.91%
POCIPrecision Optics Corporation, Inc.
$4.19-1.18%
MODDModular Medical, Inc.
$2.22-7.11%
QTTBQ32 Bio Inc.
$15.17-3.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
PLTRPalantir Technologies
$125.65+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%

Questions About MIRA

What is the current price of Mira Pharmaceuticals?

Mira Pharmaceuticals is trading at $0.61 per share.

What is the 52-week range for Mira Pharmaceuticals?

Over the past 52 weeks, Mira Pharmaceuticals has traded between $0.60 and $2.45.

How much debt does Mira Pharmaceuticals have?

As of the most recent reporting period, Mira Pharmaceuticals reported total debt of $0.00.

How much cash does Mira Pharmaceuticals have on hand?

Mira Pharmaceuticals reported $4.82M in cash and cash equivalents in its most recent financial results.

What is Mira Pharmaceuticals’s dividend yield?

Mira Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services